Company intelligence / Profile preview

Cortigent

Valencia, California, United States

Ownership: Private
Development stage: Other

Overview

Argus II, the company’s first device, provided artificial vision for >350 profoundly blind patients and was FDA-approved under a Humanitarian Device Exemption; it is now discontinued. The successor Orion system completed an initial 6-year clinical study in 2024, demonstrating encouraging safety and efficacy for artificial vision in the profoundly blind. Orion has FDA Breakthrough Device designation[1][4][6][9].

Therapeutic areas: NeurologyOphthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Cortigent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cortigent.

Explore the full profile